MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.omta.2026.201780

Медицинская библиотека · Molecular therapy. Advances · 2026

Antimetabolites synergize with non-genotoxic antibody drug conjugate conditioning in hematopoietic stem cell lentiviral gene therapy.

Okalova Jennifer, Alexander Jordan S, Patel Seema R, Branella Gianna M, Barichello de Quevedo Carlos, Baldwin W Hunter, Prince Chengyu, Chandrakasan Shanmuganathan, Brown Harrison C, Doering Christopher B, Spencer H Trent

СтатьяПеревод в очереди

Аннотация

Hematopoietic stem cell transplantation (HSCT) of genetically engineered cells is a promising treatment modality for monogenic diseases. However, hematopoietic stem cell (HSC)-directed lentiviral vector (LV) gene therapies remain limited by genotoxicities associated with standard non-targeted conditioning using irradiation or alkylating chemotherapy. We and others developed an antibody drug conjugate (ADC) with anti-CD117 and saporin (sap), which selectively depletes CD117-expressing HSC and progenitor cells (HSPCs). Since anti-CD117-sap does not generally provide engraftment comparable to conventional conditioning, we investigated the hypothesis anti-CD117-sap is not effective as a single conditioning agent due to insufficient HSPC depletion. We show anti-CD117-sap induces nearly complete residual HSPC entry into a non-G0 proliferative state and postulated agents targeting cycling cells would enhance engraftment. When we administered the antimetabolite 5-fluorouracil with anti-CD117-sap, anti-thymocyte globulin, and an immunoglobulin-degrading enzyme, we achieved >90% peripheral blood chimerism of unmodified cultured donor cells. Additional immunosuppression combined with an increase in transplanted cells further permitted ∼70% engraftment of HSPCs transduced with an LV encoding a high-expression, immunogenic factor VIII (FVIII) transgene. Copy numbers of ∼1.0 and normal FVIII plasma activity levels (>50%) by 6 months post-HSCT were achieved. Collectively, we show ADC and antimetabolite administration can augment LV-engineered HSPC engraftment by targeting cycling cells.

Для цитирования: Okalova Jennifer, Alexander Jordan S, Patel Seema R, Branella Gianna M, Barichello de Quevedo Carlos, Baldwin W Hunter, Prince Chengyu, Chandrakasan Shanmuganathan, Brown Harrison C, Doering Christopher B, Spencer H Trent. Antimetabolites synergize with non-genotoxic antibody drug conjugate conditioning in hematopoietic stem cell lentiviral gene therapy.. Molecular therapy. Advances. 2026. DOI: 10.1016/j.omta.2026.201780.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.